DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL…
Award details are derived from public USAspending.gov records. Not a bid recommendation.
Award details
- Award ID
- HT942524C0076
- Contractor
- INHALON BIOPHARMA, INC.
- Awarding agency
- Department of Defense
- Sub-agency / office
- Defense Health Agency
- Award amount
- $2,234,650
- Period of performance
- Sep 23, 2024 – Dec 22, 2026
- NAICS
- 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- PSC AN12
- Place of performance
- MORRISVILLE, NC, 275608425, USA
- Competition
- FULL AND OPEN COMPETITION · Set-aside: NO SET ASIDE USED. · 47 offers
- Pricing
- FIXED PRICE LEVEL OF EFFORT
- Financial breakdown
- Current value $2,234,650 · Obligated $2,234,650 · Potential value $2,234,650 · Latest action obligation $0
Public award description
DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL ATTACHMENT AND ENTRY REVISED STATEMENT OF WORK AND PRINCIPAL INVESTIGATOR CHANGE.
Find out who's winning similar federal contracts
Discover comparable awards, related contractors, and agency purchasing history.